Island Pharmaceuticals Ltd (AU:ILA) — Market Cap & Net Worth
Market Cap & Net Worth: Island Pharmaceuticals Ltd (ILA)
Island Pharmaceuticals Ltd (AU:ILA) has a market capitalization of $68.53 Million (AU$96.86 Million) as of May 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #20640 globally and #711 in its home market, demonstrating a -5.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Island Pharmaceuticals Ltd's stock price AU$0.36 by its total outstanding shares 269052397 (269.05 Million). Analyse ILA cash generation efficiency to see how efficiently the company converts income to cash.
Island Pharmaceuticals Ltd Market Cap History: 2021 to 2026
Island Pharmaceuticals Ltd's market capitalization history from 2021 to 2026. Data shows change from $48.54 Million to $68.53 Million (-7.18% CAGR).
Island Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Island Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
272.17x
Island Pharmaceuticals Ltd's market cap is 272.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $35.22 Million | $11.06K | -$2.83 Million | 3182.90x | N/A |
| 2023 | $18.09 Million | $1.25 Million | -$2.86 Million | 14.45x | N/A |
| 2024 | $32.36 Million | $118.91K | -$3.92 Million | 272.17x | N/A |
Competitor Companies of ILA by Market Capitalization
Companies near Island Pharmaceuticals Ltd in the global market cap rankings as of May 6, 2026.
Key companies related to Island Pharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.67 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $72.97 Billion USD.
- UCB SA (BR:UCB): Ranked #515 globally with a market cap of $51.41 Billion USD ( €43.97 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #570 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.67 Billion | $424.36 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.97 Billion | $702.27 |
| #515 | UCB SA | BR:UCB | $51.41 Billion | €231.00 |
| #570 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Island Pharmaceuticals Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Island Pharmaceuticals Ltd's market cap moved from $48.54 Million to $ 68.53 Million, with a yearly change of -7.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$68.53 Million | -16.28% |
| 2025 | AU$81.86 Million | +152.94% |
| 2024 | AU$32.36 Million | +78.95% |
| 2023 | AU$18.09 Million | -48.65% |
| 2022 | AU$35.22 Million | -27.45% |
| 2021 | AU$48.54 Million | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of Island Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $68.53 Million USD |
| MoneyControl | $68.53 Million USD |
| MarketWatch | $68.53 Million USD |
| marketcap.company | $68.53 Million USD |
| Reuters | $68.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East,… Read more